Aytu Biopharma Inc
AYTU
查看詳細走勢圖
2.550USD
+0.080+3.24%
收盤 12/19, 16:00（美東）報價延遲15分鐘
25.28M總市值
虧損本益比TTM
盤中分時
1分
30分
1小時
日k
週k
月k
日k
今天
+3.24%
5天
+10.87%
1月
+31.44%
6月
+27.50%
今年開始到現在
+50.00%
1年
+84.78%
查看詳細走勢圖
TradingKey Aytu Biopharma Inc股票評分
單位: USD 更新時間: 2025-12-19操作建議
Aytu Biopharma Inc當前公司基本面數據相對健康，增長潛力很大。當前估值合理，在藥品行業排名77/158位。機構持股佔比非常高，近一個月多位分析師給出公司評級為買入。最高目標價9.17。中期看，股價處於上升通道。近一個月，市場表現很強，技術面和基本面綜合得分較高，很強的走勢得到基本面和技術面的印證。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Aytu Biopharma Inc評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
3
分析師
買入
評級
9.167
目標均價
+309.23%
漲幅空間
數據免責聲明：分析師評級與目標價由LSEG提供，僅供參考，不應當作投資建議
Aytu Biopharma Inc亮點
亮點風險
Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing novel therapeutics. The Company's business is focused on its prescription pharmaceutical products sold primarily through third party wholesalers and pharmacies and which primarily consists of two product portfolios. The first consists of two products for the treatment of ADHD: Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets. The second consists primarily of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency.
業績增長期
公司處於發展階段，最新年度總收入66.38M美元
估值低估
公司最新PE估值-1.16，處於3年歷史低位
詹姆斯·西蒙斯持倉
明星投資者詹姆斯·西蒙斯持倉，最新持倉95.12K股
活躍度降低
近期活躍度降低，過去20天平均換手率-0.49
Aytu Biopharma Inc新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Aytu Biopharma Inc簡介
Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing novel therapeutics. The Company's business is focused on its prescription pharmaceutical products sold primarily through third party wholesalers and pharmacies and which primarily consists of two product portfolios. The first consists of two products for the treatment of ADHD: Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets. The second consists primarily of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency.
公司代碼AYTU
公司Aytu Biopharma Inc
CEODisbrow (Joshua R)
網址https://aytubio.com/
常見問題
Aytu Biopharma Inc(AYTU)的當前股價是多少？
Aytu Biopharma Inc(AYTU)的當前股價是 2.550。
Aytu Biopharma Inc 的股票代碼是什麼？
Aytu Biopharma Inc的股票代碼是AYTU。
Aytu Biopharma Inc股票的52週最高點是多少？
Aytu Biopharma Inc股票的52週最高點是2.820。
Aytu Biopharma Inc股票的52週最低點是多少？
Aytu Biopharma Inc股票的52週最低點是0.950。
Aytu Biopharma Inc的市值是多少？
Aytu Biopharma Inc的市值是25.28M。
Aytu Biopharma Inc的淨利潤是多少？
Aytu Biopharma Inc的淨利潤為-13.56M。
現在Aytu Biopharma Inc(AYTU)的股票是買入、持有還是賣出？
根據分析師評級，Aytu Biopharma Inc(AYTU)的總體評級為買入，目標價格為9.167。
Aytu Biopharma Inc(AYTU)股票的每股收益（EPS TTM）是多少
Aytu Biopharma Inc(AYTU)股票的每股收益（EPS TTM）是-2.194。
相關品種
+1.32%
-0.88%
+1.75%
+0.83%
+0.60%
+0.38%
+0.91%
+1.03%
+2.32%
+0.60%
+0.40%
+1.97%
+1.63%
+1.21%
+0.65%
+0.66%
+2.57%
0.00%
-0.44%
+1.06%
